- $144.25bn
- $197.92bn
- $28.19bn
- 84
- 36
- 59
- 62
Annual cashflow statement for Amgen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 7,842 | 7,264 | 5,893 | 6,552 | 6,717 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 122 | 135 | 1,617 | 1,683 | -560 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -731 | -216 | -1,194 | -733 | -484 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 9,150 | 10,497 | 9,261 | 9,721 | 8,471 |
| Capital Expenditures | -618 | -608 | -880 | -936 | -1,112 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 6,327 | -4,793 | 1,613 | -5,108 | -25,092 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 5,709 | -5,401 | 733 | -6,044 | -26,204 |
| Financing Cash Flow Items | -42 | -90 | -78 | -103 | -72 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -15,767 | -4,867 | -8,271 | -4,037 | 21,048 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -908 | 229 | 1,723 | -360 | 3,315 |